Major US$15B chemical company joins Alexium to commercialise Alexiflam® NF

|

Published 27-APR-2020 10:40 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Alexium International Group Ltd (ASX:AJX) has signed a Supply and Evaluation Agreement with a major flame retardant chemical company as a strategic business partner for the market launch of Alexiflam® NF.

Alexiflam® NF the company’s proprietary flame retardant treatment for cotton and cellulose-based textiles. Flame retardant (FR) cotton is a prominent segment of the protective fabrics market and presents a huge potential for AJX given global market size of FR cotton is more than 300 million sq. yards per annum.

The agreement follows an April 2019 MOU that named the US$15 billion Israel Chemicals Ltd (TASE/NYSE: ICL), a leading global specialty minerals and specialty chemicals company as the other party, following a long period of co-operation between the two.

Today’s agreement will see the parties combine their technical and market resources to launch Alexiflam® NF into target markets and it includes the following:

  • Alexium grants access to the Alexiflam® NF technology to the business partner.
  • The partnership will actively evaluate the potential market for Alexiflam® NF, develop new applications, and based on market feedback will target their sales into global FR cotton markets, including workwear.
  • Alexium will market Alexium® NF for FR socks used in foam mattresses, cotton fleece, and military uniforms.
  • Alexium will continue to manufacture Alexiflam® NF. The agreement does not specify minimum volumes or forecasted sales, and therefore the material value of the agreement cannot be calculated.
  • The manufacture of Alexiflam® NF could be transferred to the business partner should they develop the requisite manufacturing capability. Upon such a transfer, the revenue Alexium receives will become a royalty stream based on Alexiflam® NF sales, at a rate to be determined.

Today’s agreement is a key milestone for the fourth key growth pillar of Alexium’s strategic plan. Each of its key growth pillars has a clearly defined pathway to revenue, setting AJX up for commercialisation over the coming 12-18 months.

It also represents the third strategic business partner for AJX, after signing an exclusive Supply Agreement and Innovation Partnership with industry leading US bedding product manufacturer, Soft-Tex earlier this month, and an agreement with Pine Belt to develop flame retardant uniforms for the US military.

The partnership with Soft-Tex was announced earlier this month and will see Alexium’s Alexicool® cooling products provide the cooling engine for Soft-Tex’s ReactexTM technology, which manages bedding system heat flow to provide a comfortable sleep environment.

The first of AJX’s three strategic business partnerships came in March 2019 — an exclusive development agreement with uniform treatment company Pine Belt for Alexiflam® FR NyCo for applications for military uniforms.

Commenting on the new agreement Alexium CEO Dr. Bob Brookins said, “Alexiflam® NF is a product that allows us to target both traditional FR cotton markets as well as unique opportunities where traditional FR cotton treatments are not a fit. Over the past year, work with our business partner has been productive, and we have identified a strong list of target markets and customers for Alexiflam® NF.

“I look forward to working with them to drive the joint commercialisation activities. By combining Alexium’s unique & proprietary chemistry with their marketing and sales distribution infrastructure, the management team has positioned Alexium to access these flame retardant markets."



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X